The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Surgery for SCLC: current indications and future options
Rene Petersen, MD, PhD, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, explores which patients with small-cell lung cancer (SCLC) should be considered for surgery, highlighting those with limited stage disease of T1 to T2 classification. In the future, the role of surgery may expand, with the potential for salvage surgery to become an option for some patients. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
